EOSINOPHILIA and Cyclobenzaprine


EOSINOPHILIA Symptoms and Causes

Eosinophils are a type of white blood cell. They help fight off infections and play a role in your body's immune response. They can also build up and cause inflammation.

Normally your blood doesn't have a large number of eosinophils. Your body may produce more of them in response to

  • Allergic disorders
  • Skin conditions
  • Parasitic and fungal infections
  • Autoimmune diseases
  • Some cancers
  • Bone marrow disorders

In some conditions, the eosinophils can move outside the bloodstream and build up in organs and tissues. This can happen in many different parts of the body, including the esophagus, heart, lungs, blood, and intestines. Treatment of eosinophilic disorders can vary, depending on the cause and which part of the body is affected. Steroids are often part of the treatment.

Check out the latest treatments for EOSINOPHILIA

EOSINOPHILIA treatment research studies

Cyclobenzaprine clinical trials, surveys and public health registries

Find Drug Side Effect reports

Cyclobenzaprine Side Effects

Completed Suicide (160)
Toxicity To Various Agents (127)
Cardiac Arrest (64)
Respiratory Arrest (59)
Overdose (36)
Pain (28)
Cardio-respiratory Arrest (24)
Dizziness (24)
Confusional State (23)
Death (21)
Exposure Via Ingestion (20)
Nausea (18)
Fall (16)
Depression (15)
Convulsion (15)
Constipation (15)
Anxiety (14)
Hallucination (14)
Hypotension (14)
Headache (14)
Vomiting (13)
Fatigue (13)
Dry Mouth (12)
Chest Pain (12)
Deep Vein Thrombosis (12)
Dyspnoea (12)
Loss Of Consciousness (12)
Pulmonary Embolism (12)
Asthenia (11)
Heart Rate Increased (11)
Insomnia (11)
Somnolence (11)
Myoclonus (11)
Delirium (10)
Aspartate Aminotransferase Increased (10)
Coma (10)
Diarrhoea (10)
Intentional Overdose (10)
Hypoaesthesia (10)
Back Pain (9)
Alanine Aminotransferase Increased (9)
Depressed Level Of Consciousness (9)
Gait Disturbance (9)
Tachycardia (9)
Serotonin Syndrome (9)
Hepatic Function Abnormal (8)
Injury (8)
Tremor (8)
Psychotic Disorder (8)
Mental Status Changes (8)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

EOSINOPHILIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia
Conditions: Asthma;   Eosinophilia;   Helminthiasis;   Hypersensitivity;   Parasitic Disease
Outcome Measure:
2 Recruiting A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection
Condition: Loiasis
Interventions: Drug: Reslizumab;   Drug: Diethylcarbamazine
Outcome Measures: Reduction in peak eosinophil count measure during the first 7 days of DEC treatment as a percent of baseline count.;   Frequency and severity of AE's, markers of eosinophil activation proportion of subjects who clear blood microfilariae and time to clearance at 3, 7, and 28 days, rate of recurrence of microfilaremia and/or clinical symptoms.
3 Recruiting Development, Validation and Evaluation of an Adult and Pediatric Eosinophilic Esophagitis Activity Index
Conditions: Deglutition Disorders;   Esophageal Diseases;   Eosinophilia
Intervention: Other: assessment of disease activity using the EEsAI
Outcome Measures: Development of an EE Activity Index;   Evaluation and validation of the activity index
4 Recruiting A Longitudinal Study of Familial HyperEosinophilia (FE): Natural History and Markers of Disease Progression
Condition: Eosinophilia
Outcome Measure:
5 Unknown  Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
Conditions: Hypereosinophilic Syndrome;   Chronic Eosinophilic Leukemia (CEL);   Myeloproliferative Disorders
Intervention: Drug: STI571
Outcome Measures: Rate of complete response (CR) in all patients at 3rd month;   Duration of response (CR);   Overall survival at 12th month
6 Recruiting Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Interventions: Drug: benralizumab;   Drug: Placebo
Outcome Measures: Reduction of peripheral Eosinophilia at 12 weeks;   Safety;   Improvement in end organ manifestations, reduction of bone marrow eosinophils and mast cells;   Long term efficacy, pharmacokinetics, development of antidrug antibodies
7 Recruiting Comparison Between Corticosteroid and Topical Steroids in the DRESS
Condition: Drug Rash With Eosinophilia and Systemic Symptoms
Interventions: Drug: Prednisone;   Drug: Clobetasol
Outcome Measures: Rate of patients with a complete or almost healing of visceral involvement to D30 +/- 5 days AND complete or almost complete healing of skin involvement.;   Rate of patients with a complete or almost complete healing of cutaneous and visceral involvement at Day 30 ± 5 days;   Delays of complete or almost complete visceral healing;   Relapse rates and bounces rates between the end of acute treatment and M12;   Patients rate evaluating to severe form (occurrence of a criterion defining the severe form cf. Above);   Occurrence rate of moderate DRESS visceral involvement, during the initial treatment (D0 to D30) not existing at inclusion;   Mortality rate at Month 12;   Sequelae rate at Month 12;   Systemic steroids adverse reactions rate;   Topical steroids adverse reactions rate;   Patch tests evaluation in DRESS;   Reactivation kinetics of Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Herpes Simplex virus (HSV), Human Herpes virus6 (HHV6) and Human Herpes virus7 (HHV7);   Predictive value of lymphocyte transformation test in imputability;   Immunological factors evaluation in the skin;   Blood inflammatory cytokines and chemokines analysis;   Blood cytokines polymorphisms analysis
8 Recruiting Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Interventions: Drug: Dexpramipexole;   Drug: Corticosteroid Taper
Outcome Measures: A binary response indicating whether or not the subject had a greater than or equal to 50 % change in prednisone dose to maintain AEC & lt; 1000/microL and control clinical symptoms and 2) the change in minimal effective corticosteroid dose...;   Reduction in circulating eosinophils after 3 months of treatment with dexpramipexole (prior to steroid taper);   Reduction in bone marrow eosinophils and myeloid precursors after 3 months of treatment with dexpramipexole (prior to steroid taper);   Number of subjects able to taper to & lt; 10 mg prednisone and maintain AEC& lt; 1000/microL and control of clinical symptoms;   Incidence and severity of adverse events
9 Recruiting Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: Imatinib Mesylate
Outcome Measures: reduction of absolute eosinophil count to& lt; 1500/mm3;   Measures of eosinophil activation;   Resolution of bone marrow abnormalities;   Reduction or disappearance of FIP1L1/PDGFRAtranscript in applicable subjects
10 Recruiting Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
Conditions: Eosinophilic Gastrointestinal Disease Eosinophilic Inflammatory Disease;   Food Allergy
Outcome Measure:
11 Recruiting Mucosal Impedance and Eosinophilic Esophagitis
Condition: Eosinophilic Esophagitis
Intervention: Device: Mucosal Impedance
Outcome Measure: Effective treatment is defined by the elimination of esophageal Eosinophilia on follow up endoscopic biopsy.
12 Recruiting Registry for Eosinophilic Gastrointestinal Disorders (REGID)
Conditions: Eosinophilic Gastrointestinal Disorders (EGID);   Eosinophilic Esophagitis;   Eosinophils
Outcome Measure: Registry Aim
13 Recruiting Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders
Conditions: Food Hypersensitivity;   Eosinophilia;   Peanut Hypersensitivity;   Eosinophilic Gastroenteritis;   Eosinophilic Esophagitis
Outcome Measure:
14 Unknown  Identification of New Markers in the Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Biological: biologie sample
Outcome Measure: The aim is to characterize, through an approach immunoprotéomique, new HES biomarkers more informative and easier access than those currently available to us. These biomarkers will help to the diagnosis of HES, compared with other causes of Eosinophilia.
15 Unknown  Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations
Conditions: Asthma;   Viral Infection
Interventions: Drug: Mepolizumab;   Drug: Placebo
Outcome Measures: FEV1;   Questionnaire to score asthma and common cold complaints;   Viral load;   Sputum eosinophils;   Cell influx in bronchoalveolar lavage fluid;   Pro-inflammatory cytokines in bronchoalveolar lavage fluid;   Antibody production
16 Unknown  Treatment of Asymptomatic Toxocariasis With Albendazole in Children
Condition: Asymptomatic Toxocariasis
Interventions: Drug: Albendazole;   Drug: Placebo
Outcome Measures: Mean absolute reduction in eosinophil count from baseline;   Reduction in eosinophil count in more than 60% from baseline;   Incidence of adverse drug events;   Mean absolute reduction in eosinophil count
17 Recruiting Functional Activity of Airway Eosinophils in Allergic Disease
Condition: Asthma
Intervention: Biological: Segmental Allergen Challenge
Outcome Measure: The primary endpoint of this study is to use segmental antigen challenge by bronchoscopy to elicit airway Eosinophilia and to retrieve cells from the airway for analysis of their function.
18 Unknown  The Factors Associated With the Formation of Nasal polyp-a Case Control and Descriptive Study
Conditions: Nasal Polyp;   Smoking;   Rhinosinusitis;   Allergic Rhinitis;   Deviated Nasal Septum;   ASA Intolerant Asthma
Outcome Measures: Association of the antrochoanal and ethmoidal polyps with smoking, wood stove exposure, allergic rhinitis, deviated nasal septum, rhino sinusitis, non vegetarian diet,Eosinophilia and staphylococcus aureus in terms of the odds ratio.;   Gene expression profiling of Antrochoanal and Ethmoidal nasal polyps;   Mutational analysis of Antrochoanal and Ethmoidal nasal polyps;   Relationship of the nasal polyps with respect to the age, sex, religion, socioeconomic status, occupation, urban or rural preponderance, overcrowding and aspirin intolerance.;   To study the cause for recurrence of Nasal polyps
19 Recruiting Steroid Treatment for Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: Corticosteroids
Outcome Measures: GC responsiveness: defined as the lowest dose of prednisone at which eosinophils remain & lt; 1000/microl with control of symptoms, or dose at which eosinophils rebound after taper, or if there is no response, the challenge dose.;   Clinical factors associated with GC responsiveness (including HES variant, pattern of organ involvement and laboratory parameters) will be explored.
20 Not yet recruiting Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge
Conditions: Eosinophilic Esophagitis;   EoE
Outcome Measures: Cytosponge accuracy and utility;   Cytosponge safety and acceptability